# A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

> **NCT00051597** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 70 (—)

## Conditions studied

- Hodgkin Disease
- Lymphoma, Large-Cell
- Sarcoma, Kaposi
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, B-Cell

## Interventions

- **DRUG:** SGN-30 (monoclonal antibody)

## Key facts

- **NCT ID:** NCT00051597
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 70 (—)
- **Last updated:** 2011-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051597, "A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00051597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*